Bio Techne Stock One Year Return
| T1CH34 Stock | 13.08 0.00 0.00% |
Bio Techne fundamentals help investors to digest information that contributes to Bio Techne's financial success or failures. It also enables traders to predict the movement of Bio Stock. The fundamental analysis module provides a way to measure Bio Techne's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bio Techne stock.
Bio |
Bio Techne Company One Year Return Analysis
Bio Techne's One Year Return is the annualized return generated from holding a security for exactly 12 months. The measure is considered to be good short-term measures of fund performance. In other words, it represents the capital appreciation of fund investments over the last year. However when the market is volatile such as in recent years, One Year Return measure can be misleading.
More About One Year Return | All Equity Analysis
One Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Although One Year Fund Return indicator can give a sense of overall fund short-term potential, it is recommended to look at mid and long term return measure before selecting a particular fund or ETF. The great way to validate fund short-term performance is to compare it with other similar funds or ETFs for the same 12 months interval.
| Competition |
Based on the recorded statements, Bio Techne has an One Year Return of 0.0%. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Biotechnology (which currently averages 0.0) industry. This indicator is about the same for all Brazil stocks average (which is currently at 0.0).
Did you try this?
Run Global Correlations Now
Global CorrelationsFind global opportunities by holding instruments from different markets |
| All Next | Launch Module |
Bio Fundamentals
| Return On Equity | 0.15 | |||
| Return On Asset | 0.0771 | |||
| Profit Margin | 0.23 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 73.29 B | |||
| Shares Outstanding | 4.72 B | |||
| Price To Book | 7.19 X | |||
| Price To Sales | 65.05 X | |||
| Revenue | 1.11 B | |||
| Gross Profit | 758.09 M | |||
| EBITDA | 413.76 M | |||
| Net Income | 272.05 M | |||
| Total Debt | 243.41 M | |||
| Book Value Per Share | 0.38 X | |||
| Cash Flow From Operations | 325.27 M | |||
| Earnings Per Share | 0.28 X | |||
| Number Of Employees | 3 K | |||
| Beta | 1.21 | |||
| Market Capitalization | 60.28 B | |||
| Total Asset | 2.29 B | |||
| Annual Yield | 0 % | |||
| Net Asset | 2.29 B | |||
| Last Dividend Paid | 0.32 |
About Bio Techne Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bio Techne's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Techne using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Techne based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Bio Stock
Bio Techne financial ratios help investors to determine whether Bio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bio with respect to the benefits of owning Bio Techne security.